Barely Significant

Excerpts

3,685 sentences · 1 filter applied

Strengths and Weaknesses Both advantages and limitations of our study are primarily related to the retrospective cohort study design characteristics: the number of patients included in the study is somewhat significant, with 5039 women having been diagnosed with breast pathology, and the follow-up program was conducted to cover a period of 10 years (which allowed a thorough analysis of post-surgical and follow-up VTE occurrence).
Supplementary Materials The following are available online at https://www.mdpi.com/article/10.3390/cancers14051254/s1 , Figure S1 Significant and possibly significant predictors of progression-free and overall survival for PDAC; Table S1: Perioperative clinical and pathological data. 40 DP CARs.xlsx; Table S2: Relative changes in the arterial geometry after DP CAR.xlsx; Table S3: Table for all PDAC 34 Appleby. xlsx; Table S4: Survival for 31 PDAC after Appleby.xlsx Table S5: Tumor size for PDAC.docx; File S1: Statistics 1 for PDAC survival.docx; File S2: Statistics 2 for PDAC survival.docx; File S3: Statistical analysis of hemodynamic changes after DPCAR.
Patients with co-morbidities were more likely to present PCI, although only the association of having a diagnosis of a lung disease (asthma, chronic obstructive pulmonary disease, chronic bronchitis, surgery for lung cancer, pulmonary emphysema, and pneumonia) was nearly significant (age- and education-adjusted OR, 95%CI: 1.87, 0.97–3.60).
Functionally, JBS2 exerted concentration-dependent reductions in the viability of estrogen receptor (ER)-negative HER2-positive SUM-225 breast cancer cells, a DCIS-like cell model ( Figure 2 E), and it showed a trend to reduce viability in a primary culture from a DCIS patient ( Figure 2 F; p = ns).
showed a nonsignificant trend towards improved overall survival for adjuvant therapy (radiotherapy, chemotherapy, or both) in comparison to surgery without adjuvant therapy for patients with biliary tract cancers, including GBC (odds ratio [OR] 0.74; 95% CI, 0.55–1.01; p = 0.06) [ 86 ].
Treatment of Resectable Gallbladder Cancer.
Cancers (Basel) · 2022 · PMC8945892